๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leptomeningeal Metastasis
Clinical trial register · China

Leptomeningeal Metastasis Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 7 Huizhou 6 Beijing 4 Guangzhou 2 Dongguan 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai7 Huizhou6 Beijing4 Guangzhou2 Dongguan1
All 14 locations
Target enrolment
to

Leptomeningeal Metastasis trials in China

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
NCT07778940Leptomeningeal Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2
50
Tianjin
2026-09
Not yet open
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
NCT07551414NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
38
Beijing
2026-05-30
Recruiting
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NCT07348965NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
Guangzhou University of Traditional Chinese Medicine
Not applicable
42
Guangzhou
2026-03-01
Recruiting
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
NCT07398599Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University
Not applicable
30
Nanchang
2026-02-15
Recruiting
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
NCT06296745Leptomeningeal Metastasis
Guangzhou Medical University
Phase 2
36
Huizhou
2025-09-01
Not yet open
AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study
NCT07005791Lung Cancer (NSCLC), Leptomeningeal Metastasis, Intracranial Pressure
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
142
Nanjing
2025-07-01
Recruiting
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
NCT07092202Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
40
Wuhan
2025-04-15
Recruiting
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
NCT06809517Leptomeningeal Metastasis, Intrathecal Drug Delivery
Guangzhou Medical University
Phase 1/2
34
Huizhou
2025-03-18
Active, closed
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
NCT06809530Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4
Guangzhou Medical University
Phase 1/2
34
Beijing, Huizhou, Shanghai
2025-03-17
Active, closed
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
NCT06762080Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2
36
Huizhou, Beijing, Shanghai
2025-03-07
Recruiting
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
NCT06643000Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
Henan Cancer Hospital
Not applicable
60
Zhengzhou
2024-12-20
Recruiting
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
NCT06663306Lung Cancer (NSCLC), Leptomeningeal Metastasis
Shanghai Chest Hospital
Phase 1
19
Shanghai
2024-12-09
By invitation
Retrospective Study on Leptomeningeal Metastasis of Solid Tumors
NCT06705049Leptomeningeal Metastasis
Shanghai Zhongshan Hospital
Observational
107
Shanghai
2024-10-01
Active, closed
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Guangdong Association of Clinical Trials
Phase 4
41
Dongguan, Foshan, Guangzhou
2024-08-01
Active, closed
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
NCT06462222Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2
45
Huizhou, Beijing, Shanghai
2024-06-30
Recruiting
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
NCT06431685NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
Sichuan University
Phase 1
10
Chengdu
2024-04-25
Recruiting
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
NCT06230055HER2-negative Breast Cancer, Leptomeningeal Metastasis
Fudan University
Phase 4
37
Shanghai
2024-01-05
Recruiting
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
NCT06399926Leptomeningeal Metastasis, Lung Cancer
Xiangya Hospital of Central South University
Observational
64
Changsha
2023-10-30
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/leptomeningeal-metastasis

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition Leptomeningeal Metastasis.

How many Leptomeningeal Metastasis trials are recruiting in China?

12 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Leptomeningeal Metastasis), 21 studies
PhaseStudiesRecruitingShare
Phase 25223.8%
Not applicable4419%
Phase 1/24119%
Observational3114.3%
Phase 43214.3%
Phase 1229.5%

Most active sponsors

Lead sponsors with the most studies (Leptomeningeal Metastasis)
Lead sponsorStudiesRecruiting
Guangzhou Medical University63
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Fudan University11
Fujian Cancer Hospital10
Guangdong Association of Clinical Trials10
Guangzhou University of Traditional Chinese Medicine11
Henan Cancer Hospital11
Second Affiliated Hospital of Nanchang University11
Shanghai Cancer Hospital, China11
Shanghai Chest Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.